Back to top

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare System Compared to Cyclosporine 0.05% for Treating Meibomian Gl

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Sight Sciences, Inc. (SGHT)